Immunogenicity of recombinant human interleukin-2: Biological features and clinical relevance
- 1 December 1993
- journal article
- Published by Springer Nature in Biotherapy
- Vol. 6 (4) , 251-261
- https://doi.org/10.1007/bf01878354
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignanciesThe Lancet, 1990
- A New Regimen of Interleukin 2 and Lymphokine-Activated Killer CellsArchives of internal medicine (1960), 1988
- CLINICAL SIGNIFICANCE OF ANTI-IFN-α ANTIBODY TITRES DURING INTERFERON THERAPYThe Lancet, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Preliminary Results of Authentic Recombinant Somatropin Treatment in Human Growth Hormone Deficient Children. French Collaborative StudyActa Paediatrica, 1987
- Structure and expression of a cloned cDNA for human interleukin-2Nature, 1983
- ANTIBODIES TO HUMAN LEUCOCYTE INTERFERONS IN CANCER PATIENTSThe Lancet, 1983
- Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity.The Journal of Experimental Medicine, 1982
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proceedings of the National Academy of Sciences, 1979
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970